University of Virginia School of Medicine scientists are tapping the power of AI to enhance and accelerate treatment for ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Researchers, led by Dr Rafael T. M. de Rosales and Dr Graeme Stasiuk, have been awarded £10 million in funding from the ...

This early prototype was just 10 cm wide, but Lawrence’s innovation was so impactful that it earned him the 1939 Nobel Prize ...

Access Engineering PLC is poised to commence production at Sri Lanka’s first radiopharmaceutical plant by early next year, a landmark venture expected to revolutionise cancer diagnosis and treatment ...

Dopamine is a neurotransmitter often associated with pleasure and reward. It has indeed been found to play an important role in adapting us to new situations. A recent study explains how that works, ...

At June 30, 2025, the Company's cash and cash equivalents were $695.6 million, after payment of $276.4 million for the Evergreen Theragnostics, Inc. (“Evergreen”) acquisition, which closed early in ...

Beyond imaging, if Telix can crack a better therapy for the key cancers in its remit, then its $7 billion ... Read More The ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...

This NDA acceptance builds on the success of Lantheus’ market-leading PSMA PET imaging agent, PYLARIFY, which has demonstrated high diagnostic performance and meaningful impact on clinical decision ...

PET/CT is a critical tool for MM staging, treatment response monitoring, and the detection of extramedullary disease (EMD), the authors explained. PET/CT has also been found to be a valuable ...